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ABSTRACT 
Objective: To develop and validate stability indicating HPTLC method for simultaneous quantitative determination of candesartan cilexetil (CDT) 
and hydrochlorothiazide (HCT) in pharmaceutical dosage form. 
Methods: The present study deals with development and validation of stability indicating HPTLC method for simultaneous estimation of CDT and 
HCT. Chromatographic separation was performed on aluminum plate precoated with Silica Gel 60 F254 using toluene: chloroform: ethanol: glacial 
acetic acid (2:7:1:0.1 v/v) as mobile phase. The wavelength selected for densitometry scanning was 270 nm. Regression plots revealed linear 
relationships in the concentration range of 500-5000 and 400-2000 ng/band for CDT and HCT respectively. The correlation coefficient of calibration 
curves was found to be more than 0.99 for both analytes. 
Results: The chromatographic conditions gave compact spots at Rf value (±SD) 0.12 (±0.01) and 0.70 (±0.02) for HCT and CDT respectively. The 
method was validated as per International Conference on Harmonization (ICH) guidelines, demonstrating to be accurate and precise within the 
corresponding linearity range of titled analytes. Inherent stability of these drugs was studied by exposing drug substances to various stress 
conditions as per ICH guidelines namely oxidative, photolysis and hydrolytic conditions under different pH. Relevant degradation was found to take 
place under these conditions. 
Conclusion: A new simple, accurate, precise, sensitive and economic stability-indicating HPTLC method has been developed and validated for the 
simultaneous determination of CDT and HCT in pharmaceutical dosage form. The proposed method can be used for the routine estimation of CDT 
and HCT in bulk and formulation and can be employed for stability-indicating analysis. 
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INTRODUCTION 
CDT is the highly selective antagonist of angiotensin II type I 
receptor (AT1), chemically as (±)-l-Hydroxyethyl-2-ethoxy-l-[p-(o-
1H-tetrazol-5-ylphenyl)benzyl]-7-benzimidazole benzimidazole 
carboxylate cyclohexyl carbonate (fig. 1A). It is used for the 
treatment of hypertension. It is administered orally and gets rapidly 
converted to the active substance, candesartan, by ester hydrolysis 
during absorption from the gastrointestinal tract [1]. Chemically, 
HCT is 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide, which is a first line diuretic drug of the thiazide class 
(fig. 1B). It acts by lowering blood pressure initially by increasing 
sodium and water excretion. This causes a decrease in extracellular 
volume, resulting in a decrease in cardiac output and renal blood 
flow [2]. 
Literature survey reveals that several methods are reported for the 
simultaneous estimation of CDT and HCT. Various stability indicating 
methods using UPLC [3], HPLC [4-11], simultaneous estimation 
methods using HPTLC [12, 13] and UV spectrophotometric method 
[14] are available for the estimation of CDT and HCT individually or in 
combination with other drugs. There are few analytical methods such 
as HPLC [15], HPTLC [16, 17], reported for simultaneous estimation of 
the CDT and HCT in pharmaceutical preparations and biological fluids 
[18, 19] while few stability indicating HPLC methods are also reported 
[20, 21] for estimation of CDT and HCT in combination. Literature 
survey also reveals that there is not a single stability indicating HPTLC 
method available for simultaneous estimation of CDT and HCT in 
combined pharmaceutical dosage form in the presence of their 
degradation products. The HPTLC method has an advantage of 
handling a large number of samples at a time, and it is sensitive 
enough to detect a small amount of degradation products formed 
under stress conditions. Moreover, HPTLC is widely employed for the 
quantification of drugs because it has several advantages over liquid 
chromatographic methods such as low maintenance cost, short run time, 
low mobile phase consumption per sample and multiple/repeated 
scanning of chromatograms. It also facilitates automated sample 
application and scanning of the plate [22]. Thus, the aim of the present 
study was to develop an accurate, precise, specific, reproducible, 
sensitive and stability indicating HPTLC method for the simultaneous 
estimation of titled analytes. These analytes were purposely degraded by 
acid, base, oxide, heat and photodegradation to check the stability and to 
develop a stability indicating assay method [23-25]. The developed 
analytical method was validated for linearity, accuracy, precision, 
sensitivity and robustness as per ICH guidelines [26, 27]. 
 
 
Fig. 1: Structure of CDT (A) and HCT (B) 
 
MATERIALS AND METHODS 
Chemicals and reagents 
CDT and HCT standards were kindly provided by Mylan 
Laboratories, Nasik and IPCA Laboratories Ltd., Mumbai 
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respectively. The pharmaceutical dosage form used in this study was 
Candesar–H (Ranbaxy Laboratories Ltd, India) procured from the 
local market, labeled to contain 16 mg of CDT and 12.5 mg of HCT 
per tablet. The solvents and chemicals used in the study were of AR 
grade purchased from Merck Pvt. Ltd., Mumbai. The standard 
solution of CDT and HCT in methanol was scanned over the 
wavelength range 200 to 400 nm by using a UV-Visible 
spectrophotometer.  
Instrumentation 
Camag HPTLC system consisting Linomat V sample applicator, 
chromatogram development chambers (Twin Trough Chambers 20 x 
10 cm), pre-coated silica gel 60 F254 aluminium plates (20.0 x 10.0 
cm, 250 µm thickness; Merck, Germany), TLC scanner III and win 
CATS version 1.4.4 Software, (Sr. No. 1508W015) was used for 
development of chromatographic separation. 
Optimized chromatographic conditions 
Precoated silica gel 60 F254 TLC plates were used as stationary phase. 
TLC plates were prewashed with methanol and activated at 110 °C for 
10 min prior to application. Suitable volumes of standard and sample 
solutions were applied to the HPTLC plates using CAMAG Linomat V 
sample applicator (Muttenz Switzerland) equipped with 100 μl 
syringes (Hamilton, Reno, Nevada, USA) with spraying speed as 150 
nl/s. Sample and standard zones were applied to the plates as bands 
(10 mm from the bottom and 8 mm from the side edges) with band 
length of 6 mm. The chromatographic separation was achieved using 
toluene: chloroform: ethanol: glacial acetic acid (2:7:1:0.1 v/v) as mobile 
phase with chamber saturation time of 10 min and the migration 
distance of 80 mm. Separation was achieved within 10 min. The plates 
were dried to eliminate mobile phase. The wavelength used for detection 
was 270 nm where both the analytes showed optimum absorbance (fig. 
2). Densitometric scanning was performed using Camag TLC scanner III 
in the reflectance/absorbance mode at 270 nm with a slit dimension 
4.00 x 0.45 mm, scanning speed 20 mm/s and data resolution 100 
μm/step. Data was integrated using winCATS Software. 
 
 
Fig. 2: Overlay UV spectra of CDT and HCT 
 
Preparation of solutions 
Standard solution 
Standard stock solutions were prepared by dissolving 10 mg of CDT 
and HCT each in 10 ml of methanol separately to obtain a 
concentration of 1000 µg/ml. A series of solutions containing a 
mixture of drugs was prepared by transferring appropriate aliquots 
from stock standard solutions and diluting to volume with methanol. 
The concentration was fixed, taking into account the proportion in 
which CDT and HCT are present in the tablet formulation. 
Sample solutions (Assay) 
Twenty tablets were weighed and crushed to fine powder. An 
accurately weighed powder sample equivalent to 100 mg of CDT 
(78.12 mg of HCT) was transferred to a 100 ml volumetric flask and 
volume was made up to 50 ml with methanol. The solution was 
sonicated for about 20 min and volume was made with methanol. 
The resultant solution was filtered through Whatman filter paper 
No. 42. Working sample solutions were freshly prepared by diluting 
suitable volumes of the sample stock solution with methanol. The 
sample solution was analyzed six times under the optimized 
chromatographic conditions described above. A number of drugs 
was determined using a calibration curve. 
Forced degradation studies 
The study was intended to ensure the effective separation of CDT and 
HCT and their degradation peaks at the retention time of CDT and 
HCT. Forced degradation studies were performed to evaluate the 
stability indicating properties and specificity of the method. The 
objective of stress study was to generate the degradation products 
under various stress conditions and to verify that the degradation 
peaks are well resolved from the main peaks by the developed method 
[23, 24]. The stock solutions were prepared separately in methanol 
that contains 100 μg/ml of CDT and HCT. These solutions were 
subjected to stress degradation separately as per the procedures 
described below. The degradation was carried out in the dark, to 
exclude the possible degradation due to the effect of light. For thermal 
degradation and photolytic degradation, the solutions were prepared 
using 10 mg of exposed sample. The resulting solutions were applied 
on TLC plates, and the chromatograms were run under the conditions 
described above. The stress degradation studies were performed on 
the bulk drugs separately and in combination. It was also applied to 
tablet formulation to study the generation of additional degradation 
products that may arise from drug excipient interaction. 
Acid, base, wet degradation 
To 1 ml of working standard solution of CDT and HCT, 5 ml of 1N 
HCl/1N NaOH/HPLC grade water was added. The solution was 
refluxed at 60 °C for 2 h. The resultant solution was neutralized 
except wet degradation and diluted up to 10 ml.  
Peroxide oxidation 
To 1 ml of working standard solution of CDT and HCT, 5 ml of 6 % 
H2O2 was added and refluxed at 60 °C for 2 h. The resultant solution 
was diluted up to 10 ml with methanol.  
Dry heat and photo-degradation 
50 mg of CDT and HCT powder was spread as a thin layer in two 
separate Petri dishes (50 mm diameter) in two sets. The first set of petri 
dish was heated in an oven at 80 °C for 5 h. The second petri dish was 
exposed to UV radiation 200 Watt h/m2 for 28 h in the UV chamber [25].  
Validation 
The method was validated as per ICH guidelines [22, 26, 27].  
Linearity 
The appropriate volume of standard mixtures was spotted on a TLC 
plate to cover the range of 500–5000 ng/band and 400–4000 
ng/band of CDT and HCT, respectively. The analytes were resolved 
under optimized chromatographic conditions, and the standard 
calibration graph of peak area vs. concentration was plotted. The 
whole procedure was repeated thrice starting from weighing of 
analytes to preparation of the standard solution as described under 
standard solution preparation. The linearity of the method was 
evaluated by linear regression analysis, using the least square 
method. The slope and intercept were calculated. To further confirm 
linearity, F test was applied. The value of experimental Fischer ratio 
was compared against the critical value found in statistical tables, at 
the 95% confidence level. Also, the residual plot of relative response 
against concentration was plotted, and the trend was observed [28].  
Accuracy (Recovery study) 
Recovery studies were performed by the standard addition method 
where known amounts of the standard substances were spiked to 
the analyzed dosage form in triplicate. The resulting mixtures were 
analyzed by the developed method as per the procedure is given 
under assay. The base level quantity of formulation containing CDT 
and HCT used for spiking was 1600ng/band and 1250ng/band 
respectively. The % RSD (relative standard deviation) and the mean 
recovery were calculated. 
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The precision of proposed analytical method was demonstrated by 
repeatability (Intraday) and intermediate (Interday) precision studies. 
The sample preparations are containing 1600ng/band of CDT and 
1250ng/band of HCT; obtained from a homogenous sample, were 
analyzed six times on the same day (intraday precision) and on 
different days by different analysts (Interday precision). Each time the 
sample solution was prepared starting from weighing the tablet 
triturate as per the procedure described under assay. The % RSD value 
was calculated to determine any intraday and Interday variation.  
Method sensitivity (Limit of detection and limit of quantification) 
The LOD and LOQ of the developed method were calculated using 
the regression equation. A series of standard preparations 
containing 100-450 and 80-360ng/band of CDT and HCT was 
prepared over different levels. Calibration graphs were plotted for 
the obtained area under the curve of each level against the 
concentration. The LOD and LOQ were calculated using equations, 
LOD =3.3 x σ/S; LOQ =10 x σ/S, respectively where σ is the standard 
deviation of the y-intercepts and S is the slope of the calibration 
curve. Thus, obtained LOD and LOQ values were further confirmed 
by applying different volumes of stock solution (10 μg/ml) of CDT 
and HCT respectively in three replicate separately on a TLC plate 
and % RSD values were calculated. 
Specificity  
Specificity is the capacity of the method to measure the analyte 
response in the presence of its degradation products. These studies 
were performed in two parts. In Part-A, separation and resolution 
were observed between CDT and HCT. Peak purity of both CDT and 
HCT was assessed to evaluate the specificity of the method. The 
sample and standard bands were scanned at three different levels, 
i.e., peak start (S), peak apex (M), and peak end (E) positions. Peak 
purity was determined by winCATS software. In part-B, analytes 
were subjected to various stress conditions, namely, Oxidative, 
photolytic, thermolytic and hydrolytic conditions under different pH 
values. Degraded samples were applied on the TLC plates and 
developed as mentioned previously. Developed densitograms were 
observed for resolution of degraded products and spots were 
evaluated for peak purity.  
Robustness 
The robustness of an analytical method is its capacity to remain 
unaffected by small but deliberate variations in method parameters, 
and it provides an indication of its reliability during routine use. The 
HPTLC method parameters like the composition of the mobile phase, 
the volume of the mobile phase, time from spotting to development 
and time from development to scan were evaluated in this study. 
One factor at a time was changed, and the effect on the Rf and peak 
area of the drugs (1600ng/band CDT and 1250ng/band HCT) was 
studied. The % RSD was calculated.  
RESULTS AND DISCUSSION 
Development and optimization 
For the selection of an appropriate mobile phase for the effective 
separation of CDT and HCT, several runs were made by using mobile 
phases containing solvents of varying polarity, at different concentration 
levels. Several different composition of mobile phase systems like 
toluene: methanol: chloroform: Glacial acetic acid, ethyl acetate: 
chloroform: ammonia, chloroform: ethyl acetate: acetic acid, acetone: 
chloroform: ethyl acetate: methanol at different concentration 
levels/ratio were tried to achieve optimum separation of two 
component and their degradation products. The mobile phase consisting 
of toluene: chloroform: ethanol: glacial acetic acid in a ratio 2:7:1:0.1 
V/V/V was found to give the optimum resolution with sharp well-
defined peaks at Rf values of 0.12±0.006 and 0.70±0.009 for HCT and 
CDT, respectively. Dendrograms with well-resolved peaks were obtained 
without any interference from analytes or tablet excipients (fig. 3). The 
peak purity of more than 0.999 indicates that the method is specific for 
these analytes, which enable reliable results to be obtained (fig. 4). 
 
 
Fig. 3: Representative 3D densitograms acquired with A-Mobile phase, B-Diluent, C-HCT, D-CDT, E-CDT and HCT, F to M-Linearity band, N 
to Q sample solution 
 
 
A      B 
Fig. 4: Peak purity spectra of CDT (A) and HCT (B) at 270 nm 
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Forced degradation studies 
The results of the forced degradation studies are summarized in 
table 1. Under the optimized chromatographic conditions; 
degradation products of both analytes were well resolved which was 
further confirmed by peak purity study. Peak purity r (s, m) and r (s, 
e) values were above 0.999; indicating homogeneous peaks. Thus 
developed method is demonstrated to be specific. The percentage 
degradation of CDT and HCT was calculated by area normalization 
technique [22].  
During stress degradation experiments it was observed that CDT 
was more sensitive towards alkaline hydrolysis, photolysis, and 
oxidative degradation than acid hydrolysis and wet heat 
degradation. The analyte was found quite stable towards dry heat 
condition with negligible degradation. On the other hand, HCT was 
susceptible to alkaline and oxidative degradation; while, it showed 
stability towards acid hydrolysis, thermal degradation (wet and dry) 
and photolysis. Overall, CDT was found to be more sensitive towards 
degradation conditions than HCT, but both the drugs were highly 
susceptible to alkaline hydrolysis. 
  
Table 1: Summary of Forced Degradation Study for CDT and HCT 
Analyte→ 























Acid (1 N HCL, 
reflux 2 h., 60 ° C) 
0.28, 
0.54 
91.34 7.32, 1.32 0.9998, 
0.9999 
--- --- 99.73 0.9999, 
0.9994 
Base(1 N NaOH, 
reflux, 2 h, 60 ° C) 
0.45 78.84 21.16 0.9997, 
0.9999 
0.07 10.45 89.54 0.9995, 
0.9999 
Wet Heat (reflux, 2 
h, 60 ° C) 
0.43 96.52 3.71 0.9999, 
0.9998 
---- ---- 100.25 0.9998, 
0.9993 
Dry Heat (80 °C, 5 
h) 
0.29 98.04 1.96 0.9997, 
0.9998 
--- --- 100.48 0.9997, 
0.9999 
Hydrogen peroxide 
6 % (reflux, 1 h, 60 
° C) 








Photo stability 0.47 78.92 21.08 0.9999, 
0.9997 








Fig. 6: Representative densitogram showing degradation under 
basic hydrolysis 
 




Fig. 8: Representative densitogram showing degradation under 
dry heat 
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Fig. 10: Representative densitogram showing degradation 
under photo degradation 
 
Validation of the developed stability-indicating method 
The developed method was validated as per ICH guidelines for 
parameters like linearity, accuracy, precision, specificity, sensitivity 
and robustness [22, 26-28]. The 3D densitograms showed well-
resolved peaks (fig. 3). Peak purity values were found to be greater 
than 0.999 which demonstrate that there is no interference of any 
other peak of degradation products or excipients (table 1 and 4) 
indicating the specificity of the method. The linearity was evaluated 
by regression analysis, F-test and residual plots. The correlation 
coefficient was found greater than 0.99 for both the analytes. The 
calculated experimental F value was less than the critical tabulated F 
value at 95% confidence level for both the analytes (table 1). The 
plot for residuals of both the analytes did not show any tendency in 
it. These results proved that an excellent correlation existed 
between peak areas and concentration of the drugs within the 
selected concentration range. The low values of LOD and LOQ 
indicate that the developed method is sensitive to be used as a 
stability indicating. Satisfactory % mean recovery values (99 to 
102%) and lower % RSD (< 2) obtained in accuracy, precision and 
robustness studies (Table 1, 2 and 3). Thus, indicate the proposed 
method is robust to minor changes in the experimental conditions 
during routine analysis and can give accurate and precise results 
without any interference from the tablet excipients in the 
simultaneous analysis of the drugs in the formulation.  
The ICH Q1A guideline states that the validated stability indicating 
testing methods must be employed to monitor the characteristic 
features of drug substance which are susceptible to change during 
storage and are likely to affect the quality, safety and/or efficacy of 
the formulation [24]. Therefore an attempt has been made in the 
present research work, to develop stability indicating method for 
simultaneous estimation of the titled analytes. From the 
development and validation studies, it was apparent that the 
proposed method can resolve both the drug substances and their 
degradation products in short run time with optimum resolution 
and sensitivity. The published stability indicating HPLC method has 
high run-time [21] and more LOD and LOQ values indicating lower 
sensitivity in comparison to the proposed method [20, 21]. 
Extensive literature revealed that there are two HPTLC methods 
available for simultaneous estimation of CDT and HCT in bulk and 
pharmaceutical dosage form [16, 17]. Although these methods 
estimate both the analytes simultaneously and are sensitive with 
short run time but are not stability indicating to detect analytes in 
the presence of their degradation products and hence cannot be 
utilized in forced degradation studies. Thus, presented stability 
indicating HPTLC method is simple, reproducible and economical 
with the appropriate level of sensitivity to be utilized for the 
simultaneous estimation of CDT and HCT in stability studies. 
  
Table 2: Result of linearity, range, precision, method sensitivity and specificity study 
Parameter  / Analytes   CTD HCT 
Concentration range [ng/band] 500 to 5000 400 to 4000 
Retention factor [min] 0.70 0.12 
Regression equation y = 3.9617x - 9.5653 y = 7.4732x - 83.018 
Correlation coefficient [ R²] 0.996 0.997 
F ratio experimental 3.118 3.036 
F ratio tabulated  
(95% confidence level) 
3.259 
Precision 
Repeatability MR[% RSD] 100.62[NMT 1.0] 100.59[NMT 0.70] 
Intermediate precision MR[% RSD] 101.56 [NMT 1.28] 99.36 [NMT 1.05 %] 
Method sensitivity 
LOD [ng] 18.46 10.28 
LOQ [ng] 55.96 31.15 
Specificity [Typical Peak purity data] 
r[s,m]  0.9999 0.9990 
r[s,e] 0.9998 0.9998 
 
Table 3: Results of accuracy (Recovery) study by standard-addition method (n=3) 
Standard solution spiked in sample [%] CDT HCT 
Recovery level MR [%] RSD [%] MR [%] RSD [%] 
80 % 99.33 0.63 100.89 0.29 
100 % 100.73 0.72 99.15 0.97 
120 % 98.86 0.50 101.44 0.95 
MR [%]: mean recovery, n-Number of repetitions 
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Fig. 11: Residual plot for CDT and HCT 
 
Table 4: Robustness study for the developed method (n=3) 
 Condition Parameter CDT HCT 
MR [%] RSD [%] Rf MR [%] RSD [%] Rf 
Mobile phase 
Composition 
+0.1 ml 99.68 0.69 0.69 100.18 1.41 0.11 
-0.1 ml 100.03 0.81 0.69 99.28 1.20 0.11 
Amount of 
mobile phase 
+5 % 99.82 1.02 0.70 100.16 1.03 0.11 
-5 % 101.06 0.69 0.71 99.22 0.92 0.12 
Time from spotting 
to development 
+10 min 99.36 0.92 0.70 98.49 1.20 0.10 
-10 min 100.02 1.07 0.71 101.03 0.92 0.12 
Time for development 
To scanning 
+10 min 98.77 1.14 0.70 100.80       1.29 0.11 
-10 min 100.06 0.71 0.69 98.79 0.91 0.12 
 
CONCLUSION 
The HPTLC method was developed on pre-coated silica gel plates 
using toluene: chloroform: ethanol: glacial acetic acid (2:7:1:0.1 v/v) 
as mobile phase with densitometric detection at 270 nm. This study 
found that stability indicating HPTLC method for simultaneous 
determination of CDT and HCT in the combined dosage form is 
accurate, precise, linear, highly sensitive, specific and robust. The 
developed method was found suitable for determination of analytes 
in bulk and tablet dosage form without any interference from 
excipients. The forced degradation carried out as per recommendations 
of ICH guidelines shows that CDT and HCT undergo degradation to a 
different extent under different, mentioned stress conditions. The 
developed HPTLC method was found to be capable to resolve analytes in 
presence of their degradation products. In the peak purity profile 
studies, it was confirmed that the peak of the degradation product was 
not interfering with the response of the analytes. From the above study, 
we can conclude that the developed method can be employed in the 
preformulation studies, stability studies and in routine analysis of 
pharmaceutical dosage form. Thus, the presented method can be 
employed in industry and research laboratories. 
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